# Concept: Capitalised research and development expense for phase 1 for clinical research

## Bilingual Labels
- **EN**: Capitalised research and development expense for phase 1 for clinical research
- **KO**: 임상 1상 시점의 자산화된 연구개발비, 바이오 제약

- **ID**: dart:CapitalisedResearchAndDevelopmentExpenseForPhase1ForClinicalResearch

## Reported Numerical Facts

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 36,467,632,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 35,105,417,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 36,467,632,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 35,105,417,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 30,299,485,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 32,888,258,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 30,299,485,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 32,888,258,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 4,243,075,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 4,203,009,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 724,978,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 720,189,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 1,883,200,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 1,883,199,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 174,609,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 174,608,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2025-03-31**
  - **Value**: 4,283,141,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 175,419,417,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 172,712,753,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 175,419,417,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 172,712,753,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 23,895,608,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 23,784,281,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 23,895,608,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 23,784,281,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 0 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 0 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 0 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 0 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 0 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 0 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 0 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 0 (decimals: -3)

### **Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 272,208,417,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 270,576,917,000 (decimals: -3)

### **Context (Labels): Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 266,981,729,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 265,385,506,000 (decimals: -3)

## Accounting Standard References
- **Standard**: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan

---
*Source Document: entity00413046_2025-03-31.xbrl*
## Embeddable Text (for FAISS)
```text
Concept: Capitalised research and development expense for phase 1 for clinical research
Bilingual Labels
 EN: Capitalised research and development expense for phase 1 for clinical research
 KO: 임상 1상 시점의 자산화된 연구개발비, 바이오 제약
 ID: dart:CapitalisedResearchAndDevelopmentExpenseForPhase1ForClinicalResearch
Reported Numerical Facts
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 36,467,632,000 (decimals: 3)
 Period: 20250331
   Value: 35,105,417,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 36,467,632,000 (decimals: 3)
 Period: 20250331
   Value: 35,105,417,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 30,299,485,000 (decimals: 3)
 Period: 20250331
   Value: 32,888,258,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 30,299,485,000 (decimals: 3)
 Period: 20250331
   Value: 32,888,258,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 4,243,075,000 (decimals: 3)
 Period: 20250331
   Value: 4,203,009,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 724,978,000 (decimals: 3)
 Period: 20250331
   Value: 720,189,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 1,883,200,000 (decimals: 3)
 Period: 20250331
   Value: 1,883,199,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 174,609,000 (decimals: 3)
 Period: 20250331
   Value: 174,608,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20250331
   Value: 4,283,141,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 175,419,417,000 (decimals: 3)
 Period: 20250331
   Value: 172,712,753,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 175,419,417,000 (decimals: 3)
 Period: 20250331
   Value: 172,712,753,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 23,895,608,000 (decimals: 3)
 Period: 20250331
   Value: 23,784,281,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 23,895,608,000 (decimals: 3)
 Period: 20250331
   Value: 23,784,281,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 0 (decimals: 3)
 Period: 20250331
   Value: 0 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 0 (decimals: 3)
 Period: 20250331
   Value: 0 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 0 (decimals: 3)
 Period: 20250331
   Value: 0 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 0 (decimals: 3)
 Period: 20250331
   Value: 0 (decimals: 3)
Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 272,208,417,000 (decimals: 3)
 Period: 20250331
   Value: 270,576,917,000 (decimals: 3)
Context (Labels): Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 266,981,729,000 (decimals: 3)
 Period: 20250331
   Value: 265,385,506,000 (decimals: 3)
Accounting Standard References
 Standard: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan
Source Document: entity00413046_20250331.xbrl
```